Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) shot up 3.7% during mid-day trading on Monday . The stock traded as high as $7.23 and last traded at $7.22, with a volume of 90,536 shares traded. The stock had previously closed at $6.96.

Several brokerages recently issued reports on ADAP. Zacks Investment Research downgraded Adaptimmune Therapeutics PLC – from a “hold” rating to a “sell” rating in a report on Thursday, August 11th. Leerink Swann reiterated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a report on Sunday, April 24th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $15.94.

The stock’s 50-day moving average price is $7.99 and its 200 day moving average price is $8.63. The firm’s market capitalization is $510.36 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last issued its quarterly earnings data on Monday, August 8th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.16. Analysts expect that Adaptimmune Therapeutics PLC – will post ($1.16) earnings per share for the current fiscal year.

In other Adaptimmune Therapeutics PLC – news, Director Orbimed Advisors Llc acquired 1,712,400 shares of the business’s stock in a transaction dated Tuesday, May 24th. The shares were purchased at an average cost of $10.42 per share, for a total transaction of $17,843,208.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in Adaptimmune Therapeutics PLC – stock. Marshall Wace LLP acquired a new position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 140,983 shares of the company’s stock, valued at approximately $1,700,000. Marshall Wace LLP owned approximately 0.20% of Adaptimmune Therapeutics PLC – at the end of the most recent quarter.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.